BTIG Reiterates a Buy Rating on Adaptive Biotechnologies (ADPT)

In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Adaptive Biotechnologies (ADPTResearch Report), with a price target of $17.00. The company’s shares closed last Thursday at $11.36, close to its 52-week low of $5.96.

According to TipRanks.com, Massaro is a 3-star analyst with an average return of 0.9% and a 45.7% success rate. Massaro covers the Healthcare sector, focusing on stocks such as MDxHealth S.A. Sponsored ADR, Ginkgo Bioworks Holdings, and Castle Biosciences.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Adaptive Biotechnologies with a $14.50 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Adaptive Biotechnologies’ market cap is currently $1.41B and has a P/E ratio of -6.08.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.

Read More on ADPT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More